advanced search
2023_Jun_Connect_in_Pharma_leaderboard

WEARABLE INJECTORS90

Issue No #90  September 10th, 2018


Download PDF


Inside the magazine

WEARABLE INJECTORS: THE PERCEPTION OF INHERENT EXPENSE AND COMPLEXITY
WEARABLES
Jesper Roested
Subcuject
WEARABLE INJECTORS: THE PERCEPTION OF INHERENT EXPENSE AND COMPLEXITY
There is a widespread belief that wearable injectors are too expensive and complex to really take off as a commercially viable method of drug delivery. Jesper Roested tackles the causes of this belief, and explains why it is not truly the case.
2014 TO 2018: AN UPDATE ON THE STATE OF WEARABLE INJECTORS
EXPERT VIEW
Paul Jansen
2014 TO 2018: AN UPDATE ON THE STATE OF WEARABLE INJECTORS
Looking back on the developments in large volume injectors since his article in ONdrugDelivery’s 2014 issue on wearable injectors, Paul Jansen reflects on the state of this technology space today, how it has progressed and the value it is likely to offer.
BIOLOGIC DRUGS AND THEIR DELIVERY SYSTEMS: A SYMBIOSIS KEY TO COMMERCIAL SUCCESS
WEARABLES
Dr Jeannie Joughin
Enable Injections
BIOLOGIC DRUGS AND THEIR DELIVERY SYSTEMS: A SYMBIOSIS KEY TO COMMERCIAL SUCCESS
Jeannie Joughin discusses the ever-growing importance of the delivery system in the biologic combination product area, highlighting how it is the delivery system, not the drug, that defines the patient experience.
CUSTOMISED SOLUTIONS FOR LARGE-VOLUME INJECTORS
WEARABLES
Dr Paul Senn
Sensile Medical
CUSTOMISED SOLUTIONS FOR LARGE-VOLUME INJECTORS
Paul Senn discusses the products and philosophy of Sensile Medical, a developer of large volume injection devices utilising a patented micro pump technology.
YPSODOSE: SIMPLIFYING LARGE-VOLUME PATCH INJECTION FOR PHARMA COMPANIES AND PATIENTS
WEARABLES
Ian Thompson
Ypsomed
YPSODOSE: SIMPLIFYING LARGE-VOLUME PATCH INJECTION FOR PHARMA COMPANIES AND PATIENTS
Ian Thompson provides an update on YpsoDose, a new prefilled large-volume patch injector platform, and how it is designed to simplify the approach to wearable patch injectors for both pharma companies and patients.
DEVICE TRAINING AND ONBOARDING CONSIDERATIONS FOR ON-BODY DELIVERY SYSTEMS
WEARABLES
Joe Reynolds
Noble
DEVICE TRAINING AND ONBOARDING CONSIDERATIONS FOR ON-BODY DELIVERY SYSTEMS
Joe Reynolds explains how on-body injection devices have arisen from the need to develop viscous, large-volume biopharmaceutical therapies, and how Noble’s on-body training devices can help patients learn how to use their devices correctly, reliably and safely.
THE CHANGING LANDSCAPE OF WEARABLE DRUG CONTAINMENT AND DELIVERY
WEARABLES
Graham Reynolds
West Pharmaceutical Services
THE CHANGING LANDSCAPE OF WEARABLE DRUG CONTAINMENT AND DELIVERY
Biologics and biosimilars are set to make waves in the pharmaceutical arena, but these drugs can be very difficult to deliver in a patient-centric way. Wearable injectors offer a solution to the large, infrequent dosing regimens these drugs often demand. Graham Reynolds explains more.
DRUG DELIVERY MEETS AUTOMOTIVE ENGINEERING
WEARABLES
Thomas Mayer
Sonceboz
DRUG DELIVERY MEETS AUTOMOTIVE ENGINEERING
Thomas Mayer discusses Sonceboz’s activity in the world of wearable injectors and how the company’s experiences in the automotive industry and its in-house development of high-quality motors provide significant advantages for the design and production of wearable devices.
MOBILE DEVICES AND USE-RELATED RISK – TIME TO REINSTATE DETECTABILITY?
EXPERT VIEW
Richard Featherstone
Emergo By UL
MOBILE DEVICES AND USE-RELATED RISK – TIME TO REINSTATE DETECTABILITY?
Richard Featherstone makes the case for designing detectability into the user interfaces of wearable devices, enabling the user to be an active part of ensuring the device operates safely, as intended.
Top